VALENCIA, Calif.--(BUSINESS WIRE)--MannKind Corporation (Nasdaq: MNKD) unveiled new data on its drug delivery, device and particle technologies demonstrating the bioequivalence, ease of use and efficiency of the company’s novel platform. The proprietary technology, founded on the company’s expertise in inhaled drug development, device engineering and powder formulation performance, was evaluated in four separate studies presented at the 10th annual meeting of the Diabetes Technology Society in Bethesda, Maryland, November 12-13. The first application of this technology, the novel, ultra rapid-acting insulin AFREZZA® (insulin human [rDNA origin]), is currently under review by the U.S. Food and Drug Administration (FDA) and has a PDUFA date of December 29, 2010.
